Ocugen Partner Bharat Biotech Says Trial Data in 2-18 Years Age Group for Covaxin Has Been Thoroughly Reviewed by India's Central Drugs Standard Control Organisation and Have Provided Positive Recommendations; Says Now Await Further Regulatory Approvals from CDSCO Prior to Product Launch and Market Availability of Covaxin for Children

Create Account

Dark

chart

exchange

Check out our Level2View

Ocugen Partner Bharat Biotech Says Trial Data in 2-18 Years Age Group for Covaxin Has Been Thoroughly Reviewed by India's Central Drugs Standard Control Organisation and Have Provided Positive Recommendations; Says Now Await Further Regulatory Approvals from CDSCO Prior to Product Launch and Market Availability of Covaxin for Children

Benzinga | Oct 12, 2021 05:38AM EDT